News
BMY
54.23
+1.84%
0.98
Bristol Myers Squibb: The Comeback Is Unfolding
Bristol-Myers Squibb's market capitalization has declined significantly due to the impending expiration of patents for its flagship drugs. The company is undervalued by 14.2% and is expected to rise 20% by the end of 2024 or 2025. Bristol-myers is facing a looming internal crisis as several of its drugs are set to lose their exclusive patents by 2028. But the company's acquisition of Karuna Therapeutics, Inc. Shows growth prospects for the future.
Seeking Alpha · 13h ago
Bristol Myers drug Zeposia fails Phase 3 study for Crohn's disease
Bristol Myers drug Zeposia fails Phase 3 study for Crohn's disease. The drug is already approved for the treatment of multiple sclerosis and ulcerative colitis. The study failed to meet its primary endpoint of clinical remission at week 12 for the drug.
Seeking Alpha · 13h ago
Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial
Bristol Myers Squibb's said a trial of its drug Zeposia to treat Crohn's disease didn't meet its goals. The drug is approved for treatment of multiple sclerosis and ulcerative colitis. The company says the trial failed to reach its primary endpoint.
Dow Jones · 13h ago
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint Of Progression-Free Survival For Patients With Pretreated KRASG12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Bristol Myers Squibb announces results of pivotal Phase 3 KRYSTAL-12 study. KRAZATI (adagrasib) met primary endpoint of progression-free survival for patients with KRASG12C-mutated non-small cell lung cancer. The U.S. FDA granted accelerated approval for the drug in December 2022.
Benzinga · 14h ago
Bristol Myers' bowel disease drug fails to meet main goal in late-stage study
Bristol Myers' bowel disease drug fails to meet main goal in late-stage study. Drug to treat Crohn's disease, a chronic inflammatory bowel condition, did meet the main goal. Bristol Myers Squibb's experimental drug to treat the disease did meet goal in study.
Reuters · 14h ago
Bristol Myers Squibb Provides Update On First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia For Crohn's Disease; Study Did Not Meet Its Primary Endpoint Of Clinical Remission At Week 12
Benzinga · 14h ago
Is Bristol Myers Squibb Stock a Buy?
Bristol Myers Squibb's shares have dropped by 22% over the past year. The drugmaker's revenue declined by 2% year over year to $45 billion. Bristol Myers faces a number of patent cliffs by the end of the decade. The company is developing new drugs and has a solid dividend program.
The Motley Fool · 22h ago
After Hours Most Active for Mar 27, 2024 : ESPR, TLT, QQQ, KDP, KO, BMY, AAPL, AMZN, VSTS, WMT, CVX, BAC
NASDAQ · 1d ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
Barchart · 1d ago
Merck Scores Major Drug Approval, Easing Pain From Keytruda Patent Expiration
FDA approves Merck's new drug Winrevair. The drug treats a rare heart condition. Merck shares are up 3.9%. The drug is expected to be a blockbuster for the company. The approval comes as Merck braces for the loss of patents on its cancer drug Keytruda.
Barron‘s · 1d ago
BUZZ-Merck hits record high as FDA approves therapy for rare lung condition
Merck's shares MRK.N rise 4.6% to $131.32, its highest ever. FDA approves drugmaker's treatment for rare lung condition. Therapy called Winrevair to be used for treating adults with high blood pressure due to constriction of lung arteries.
Reuters · 1d ago
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
FDA approves Merck & Co's Winrevair for adults with pulmonary arterial hypertension (PAH) The therapy is designed to increase exercise capacity and reduce the risk of clinical worsening events. The company expects the therapy to reach peak sales of $5 billion by 2030.
Benzinga · 1d ago
BUZZ-Merck up as FDA approves therapy for rare lung condition
Merck's shares MRK.N rise 5% to $131.3 premarket. U.S. FDA approves drugmaker's treatment for rare lung condition. Therapy called Winrevair to be used for treating adults with high blood pressure due to constriction of lung arteries.
Reuters · 2d ago
BTIG upgrades Nuvation to buy, cites AnHeart acquisition
Seeking Alpha · 2d ago
Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock
AstraZeneca PLC announced it will buy Canadian drug developer Fusion Pharmaceuticals for $2.4 billion. The company is a specialist in cancer treatments. Fusion is developing next-generation radioconjugates, which deliver a radioactive isotope directly to cancer cells. AstraZeneca will take over Fusion's manufacturing and supply chain.
Barchart · 2d ago
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
Bristol Myers Squibb unveils a $1.8 million initiative to advance health equity in four countries with underserved patient needs. The new health equity grants are an extension of the company's commitment to invest $150M in health equity by 2025. The initiative will address social determinants of health in Brazil, India, Thailand, and the United Kingdom.
Barchart · 3d ago
2 More Potential Biotech Buyout Targets
Oncology is projected to reach $375 billion in sales by 2027. The oncology space continues to be a hot and active area for M&A activity. Exelixis is one of two smaller companies that appear to be logical buyout targets for larger companies. The company is a mid-cap oncologist with a strong pipeline.
Seeking Alpha · 3d ago
Merck to Soon Learn if Acceleron Bet Pays Off -- Market Talk
FDA in September granted priority review to Merck's application for sotatercept for pulmonary arterial hypertension. The agency has a target action date of Tuesday for a decision on the drug. Merck has said the drug would be the first in its class to address the rare and progressive disease.
Dow Jones · 3d ago
Weekly Report: what happened at BMY last week (0318-0322)?
Weekly Report · 4d ago
Sanofi: My Top Pick In Big Pharma
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.